PRESS

T.A. Sciences Announces Global Licensing Agreement with Geron for Small Molecule Telomerase Activators

Exclusive License for Non-Therapeutic Applications of Telomerase Activation

NEW YORK, March 12, 2007 -- Telomerase Activation Sciences, Inc. (T.A. Sciences) today announced a licensing agreement between its parent company, Asia Biotech Corporation (ABC), and Geron Corporation in which ABC is granted exclusive global rights to develop and market non-therapeutic products in the fields of dietary food supplements, nutraceuticals and topically applied cosmetics and cosmeceuticals using Geron's small molecule telomerase activators. Terms of the license agreement were not announced.

T.A. Sciences is opening the T.A. Sciences Center in Manhattan on April 2, 2007. Customers will be able to purchase T.A. Sciences' first product, a nutraceutical containing the telomerase activating agent "TA-65," as part of a year-long program called the "Patton Protocol."

"T.A. Sciences is very pleased to launch a telomerase activator product," said Noel Thomas Patton, founder of T.A. Sciences. "A natural consequence of aging is the shortening of telomeres (caps of DNA located at the ends of all chromosomes), which ultimately results in loss of cell function. Telomerase activation offers the potential of reducing or reversing telomere shortening. Our goal is to provide these benefits to customers who take our TA-65 nutraceutical and to help them achieve longer healthspans."

Scientists at Geron, which has been the recognized leader in telomerase research since its foundation in 1992, have been able to restore and enhance cell function in laboratory experiments by activating telomerase. T.A. Sciences has taken these experiments further and observed beneficial effects in human subjects.

"We are very excited to gain exclusive rights to the use of TA-65 in the fields provided in our license from Geron," said David Cross, T.A. Sciences' executive vice president. "TA-65 is a single molecule derived from the root of a traditional Chinese herb. Geron has shown that TA-65 activates telomerase in certain human cells. Our company is committed to using this leading edge technology to develop first-to-market, safe, efficacious products, with an initial emphasis on anti-aging nutraceuticals and topical anti-aging cosmetics."

TA Therapeutics, a Hong Kong company formed as a joint venture between Geron and the Biotechnology Research Corporation of Hong Kong University of Science and Technology, holds a global exclusive license for the therapeutic use of telomerase activators. TA Therapeutics and T.A. Sciences are not related.

About T.A. Sciences:
On April 2 T.A. Sciences is opening the T.A. Sciences Center at 24 E. 64th Street in New York. The company will offer its telomerase-activating products as part of the 12 month "Patton Protocol." The driver of T.A. Sciences' product line is the telomerase-activating small molecule "TA-65," sold under license from Geron. T.A. Sciences is privately held.

For more information on T.A. Sciences visit www.TASciences.com
For more information on Geron visit www.Geron.com